Recent Development News: Q1 – 2017

ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia

ContraFect Corporation (NASDAQ:CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the initiation of an international Phase 2 study evaluating its first-in-class lysin, CF-301, as a potential … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

ContraFect Chairman and CEO Steven C. Gilman Takes Temporary Medical Leave

ContraFect Corporation (NASDAQ: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Steven C. Gilman, Ph.D., the Company’s Chief Executive Officer and Chairman of … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Aevi Genomic Medicine Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today recent progress and financial results for the three and twelve months ended December 31, 2016.

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Edge Therapeutics to Present at Cowen and Company 37th Annual Healthcare Conference on March 8, 2017

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced that Brian A. Leuthner, President and Chief Executive Officer, will make a corporate presentation at Cowen and Company’s 37th … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

root9B Remains #1 on the Cybersecurity 500 For 5th Consecutive Quarter

In response to remaining #1 on the Cybersecurity 500 for Q1 2017, root9B’s Chief Executive Officer Eric Hipkins issued the following statement: “root9B is extremely proud to remain as the #1 company on the Cybersecurity 500 for the fifth consecutive … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

root9B Holdings to Participate in 29th Annual ROTH Conference

root9B Holdings, Inc. (NASDAQ: RTNB) (“Company”) today announced that it will attend the 29th Annual ROTH Conference in Dana Point, CA. The Company’s management will conduct one-on-one meetings with interested investors throughout the day on Monday, March 13, 2017 and … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Edge Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions, today announced financial results and corporate highlights for the fourth quarter and full-year ended December 31, 2016.

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

X4 Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Paula Ragan, PhD, President and Chief Executive Officer, will present at the Cowen and … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Aevi Genomic Medicine to Present at the Cowen and Company 37th Annual Health Care Conference

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Monday, March 6, 2016 at … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Edge Therapeutics Announces Conference Call on March 2, 2017 to Discuss Fourth Quarter and Full Year 2016 Financial Results

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced that it will host a conference call on Thursday, March 2, 2017 at 8:30 a.m. ET to discuss its … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Aevi Genomic Medicine Announces Expansion of its Collaboration with The Children’s Hospital of Philadelphia

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that it has strengthened its discovery and research platform by extending its genomics collaboration with the Center for Applied Genomics (CAG) at Children’s Hospital of Philadelphia (CHOP). The amendment to … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Edge Therapeutics Appoints Alyssa Wyant as Senior Vice President, Regulatory Affairs and Makes Inducement Grant under NASDAQ Rule 5635(c)(4)

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced the appointment of Alyssa Wyant as Senior Vice President, Regulatory Affairs. Ms. Wyant will oversee all facets of Edge’s … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Edge Therapeutics’ EG-1962 Data To Be Presented at International Stroke Conference 2017

Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of acute, life-threatening conditions, today announced that two posters on Edge’s lead product candidate, EG-1962, will be presented at the International Stroke Conference (ISC) 2017 … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Aevi Genomic Medicine Announces 2017 Investor Day

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced that it will host an Investor Day with senior management and key opinion leaders to discuss AEVI-001 and opportunities in the ADHD market. The event will be held at the NASDAQ … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Lisa Ricciardi To Join Board of Directors

ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, announced today that it has appointed Lisa Ricciardi to its Board of Directors. Ms. Ricciardi is a … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Centrexion Therapeutics to Present at the 19th Annual BIO CEO & Investor Conference

Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced its participation in the 19th Annual BIO CEO & Investor Conference taking … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Aevi Genomic Medicine to Present at the Leerink Partners 6th Annual Global Healthcare Conference

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola, President and Chief Executive Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 10:30 a.m. EST at … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Cerecor Engages SunTrust Robinson Humphrey to Assist with Review of Strategic Alternatives

Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has initiated a process to explore and review a range of strategic … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that the first patient has been dosed in a Phase 1/2 clinical trial to assess the efficacy of its lead investigational drug, AEVI-001 (NFC-1), in children with 22q11.2 Deletion Syndrome … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced the initiation of a Phase 2/3 study with the first patient dosed with X4P-001-LD for … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Cerecor Announces At-the-Market Equity Offering Program

Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has entered into an equity distribution agreement with Maxim Group LLC (“Maxim”), … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

X4 Pharmaceuticals Announces Initiation of Clinical Study of X4P-001 in Combination with Opdivo for Patients with Advanced Clear Cell Renal Cell

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer, today announced dosing of the first patient in a Phase 1/2 study … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

X4 Pharmaceuticals Appoints Dr. Sudha Parasuraman as Chief Medical Officer

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today announced the appointment of Dr. Sudha Parasuraman as Chief Medical Officer. Dr. Parasuraman is a board-certified … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

root9B Awarded 5-Year Training Subcontract Supporting Department of Defense

root9B, a root9B Holdings Inc. (NASDAQ: RTNB) company, and leading provider of advanced cybersecurity services and training for commercial and government clients, announced today that it is part of a team with Chiron Technology Services, Inc. that was awarded a … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

root9B Holdings, Inc. (Nasdaq: RTNB) to Ring The Nasdaq Stock Market Opening Bell

root9B Holdings, Inc. (RTNB) a leading provider of cybersecurity and regulatory risk mitigation services, will visit the Nasdaq MarketSite in Times Square.

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Aridis Pharmaceuticals Receives Award from the Cystic Fibrosis Foundation Therapeutics to Advance Panaecin™

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today it has secured a therapeutics development award from Cystic Fibrosis Foundation Therapeutics (CFFT), the drug discovery and development affiliate of … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

ContraFect Provides Program Update

ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today provided an update on its clinical development timeline for CF-301. The company now expects … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Aridis Pharmaceuticals Reports Positive Clinical Data from Phase 1/2a Study of Human Monoclonal Antibody AR-301 for Treating Pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, today announced positive clinical results from its Phase 1/2a study of AR-301, its fully human monoclonal antibody against Staphylococcus aureus alpha-toxin being … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

ContraFect To Present at Biotech Showcase 2017 Conference

ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, announced today that Steven C. Gilman, PhD, the Company’s Chairman and Chief Executive Officer, will … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off

Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGIuR+ ADHD Adolescents

Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that enrollment is complete in the SAGA (Study of Adolescent Glutamate Receptor Network Copy Number Variant ADHD) trial. All ongoing patients are expected to continue through the follow-up period in … Continue reading

Posted in Recent Development News: Q1 - 2017, Recent Developments | Comments Off